All News
Targeting PD-1 in Rheumatoid Arthritis
The results of the large Phase 2b RENOIR trial showed that rosnilimab, a monoclonal antibody targeting PD-1, was effective in moderate-to-severe rheumatoid arthritis (RA) patients.
Read Article
Growing Physician Enthusiasm for AI in Healthcare
The AMA has just published the results of a U.S. Physician survey and shown MD attitudes have positively shifted regarding the use of artificial intelligence (AI) in healthcare.
Read Article
The Cartel is Coming for Rheumatology
"What Do Blockbuster Drugs & The Black Market All Have in Common?" asked Dr. Madelaine Feldman at RheumNow Live 2025. They thrive, she explained, on market exclusivity "... until they don't." At first glance, the pharmaceutical marketplace may not appear like a crime drug ring, but Dr. Feldman of Tulane University described how sinister forces of market manipulation have negatively impacted patient care for years.
Read Article
JAMA Review on Dx & Rx of Monoclonal Gammopathy of Undetermined Significance. MGUS has NO Sxs or organ damage. MGUS & Dz associations (OP, Autoimmune) were likely overestimated; M protein testing should be done if malignancy or MGCS is suspected. Risk of progression to malignancy… https://t.co/Jikc5q3BJL https://t.co/hxhcD4bJ2X
Dr. John Cush RheumNow ( View Tweet)
Valentine RNL 2025 Review (2.14.2025)
Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.
https://t.co/EDCqmtbkyC https://t.co/2GlrslkgGp
Dr. John Cush RheumNow ( View Tweet)
That's not my problem - or is it? Multimorbidity in RA
RA can look so easy on the television commercials where patients appear young, healthy, and vibrant on the advertised treatment.
https://t.co/4lSVKeRtyx https://t.co/Xa1UGbJigy
Dr. John Cush RheumNow ( View Tweet)
SLE pts have increased risk of atherosclerotic cardiovascular disease (ASCVD). Systemic inflammation & glucocorticoid exposure are significant drivers of ASCVD in SLE. Screening recommended - Framingham Risk Score, ACC/AHA risk score & others reviewed https://t.co/jJHNJOU606 https://t.co/JJxiBczMwi
Dr. John Cush RheumNow ( View Tweet)
Prevalence of Systemic sclerosis–associated interstitial lung disease (SSc-ILD) was 49.8% - Chinese study of 223 SSc (F/U 8.1 yrs). Among SSc-ILD, 64% had progressive disease w/ elevated CRP at Dx as predictor. Overall mortality rate = 24.2% (pneumonia) w/ predictors of age,… https://t.co/Lb98KziPOj
Dr. John Cush RheumNow ( View Tweet)
Full read review of association betw #RA & Chikungunya fever (viral infxn transmitted by Aedes mosquitoes). Theres no true link betw RA & CHIKV; but incidence of RA after CHIKV is 13.7% (based on 16 reports, 2879 pts, 449 RA postCHIKV) https://t.co/8fxIS846Nd https://t.co/YD1aLIVrrI
Dr. John Cush RheumNow ( View Tweet)
NRMP Publishes 2025 Match Results. Rheumatology Stats:
- Ped Rheum #5 in # U.S. DO grads (30%)
- Adult Rheum #5 in Intl Med school grads (34%)
- Adult: 3/132 progr. went unfilled (Ped: 20/36 unfilled)
https://t.co/AsfOZMydMK https://t.co/Dim3hCLzXC
Dr. John Cush RheumNow ( View Tweet)
8 fold risk of incident ILD in #RA pts. Data from Korean National Health Insurance, 52,325 RA pts & 261,625 controls & 4.4 yrs F/U - ILD in 3.7% of RA vs 0.5% controls (adjHR 7.84); higher in seropositive RA (aHR= 9) vs seronegative RA (aHR=4.8) https://t.co/iIoZOwFYEN https://t.co/HBzSg9KrpZ
Dr. John Cush RheumNow ( View Tweet)
Survey on Corticosteroid (CS) use in PFAPA syndrome included 144 MDs (67% pedi-Rheums); 92% use CS in PFAPA flares. 42% expected a response w/in 12 hrs. 31% use CS ‘routinely. Med literature cites Prednisone as most preferred CS (48%). Response to CS ~ 95% https://t.co/V1wkhNaNAP https://t.co/YILAlKrUcQ
Dr. John Cush RheumNow ( View Tweet)
Lupus flares after ESRD? Metanalysis of 34 studies (29 on HD/PD; 5 post transplant/KT) - extra-renal flares seen in 36% of ESRD pts & were significantly higher w/ PD/HD vs KT (OR: 4.36; 1.66-11.47, p=0.0028). Recurrence of LN after KT was 3.4% https://t.co/tXlyxsfvXd https://t.co/tzsMCeRkz4
Dr. John Cush RheumNow ( View Tweet)
EGPA in 2025
Eosinophilic Granulomatosis with Polyangiitis (EGPA), the artist formerly known as Churg-Strauss syndrome, remains somewhat of a rogue agent among the vasculitides.
https://t.co/4ofjQRYsMH https://t.co/PoVhaQ9QiZ
Links:
Dr. John Cush RheumNow ( View Tweet)
TheDaoIndex @KDAO2011
80% #hydradenitis suppurativa pts are smokers or former smokers, smoking can predate #HS by 4-5 years. Other associations: DM-2, Spa, obesity, SAPHO, PCOS eval for SCC (squ. cell CA) #RNL2025 https://t.co/XHrFseiAMK
Dr. John Cush RheumNow ( View Tweet)
Janet Pope @Janetbirdope
#Disease #activity in #axSpA
#ASDAS - a crude measure of activity in
#ankylosing #spondylitis
Is related to #radiographic #progression
👇
⬆️ CRP May be more predictive
#ClinicalPearl #RNL2025 https://t.co/34wrMuz9mO
Dr. John Cush RheumNow ( View Tweet)
Eric Dein @ericdeinmd
Active Morphea: - MTX +/- steroids. If not effective, MMF/RTX/ABA - Topicals for circumscribed - Phototherapy Most pts achieve remission in active in 1 year Inactive morphea - Can address with PT, pain rx, psychological support, plastic surgery fat… https://t.co/OMGt8feO0z https://t.co/yWAgY2Z4Ng
Dr. John Cush RheumNow ( View Tweet)
Eric Dein @ericdeinmd
How do you know if Morphea is active? -Erythema -Peripheral induration -New lesions in the past few month Non-active damage? - Dermal atrophy -SQ atrophy -Hyperpigmentation -Skin thickness center #RNL2025
Dr. John Cush RheumNow ( View Tweet)
Eric Dein @ericdeinmd
#RNL2025 Treatment of sclerosing skin conditions: Active inflammation? Sclerotic? Atrophic? Target based on activity, depth of involvement and other disease involvement
Dr. John Cush RheumNow ( View Tweet)
MD Survey: Who should manage patients with hidradentis supprativa?
Dr. John Cush RheumNow ( View Tweet)